Introduction
The T-box family of transcription factors are highly conserved through evolution and based on phylogenetic analysis, the T-box gene family is divided into five subfamilies, namely Brachyury (T), T-brain (Tbr1), TBX1, TBX2, and TBX6 (1) . Members of this family are defined by a unique DNA binding domain known as the T-box which in vitro, binds a partially palindromic sequence T(G/C)ACACCT AGGTGTGAAATT, known as the T-element, as well as single T-element half sites in multiple orientations (2) . In vivo data have, however, revealed that the T-element binding site is highly variable and degenerate and there is evidence that T-box factors can also bind their target genes through co-factor binding sites (3, 4) . Members of the T-box family have wellestablished roles in the development of vertebrate and invertebrate species where they are expressed in a wide array of tissues and their functions range from early cell-fate decisions to organogenesis (5) . Their critical roles in development are evident by the number of human congenital developmental syndromes associated with mutations in T-box genes (6) . In addition, there is overwhelming evidence implicating T-box factors in cancer biology where they behave as oncogenes and/or tumour suppressors (7).
TBX3
The T-box transcription factor, TBX3, is critical for development and has emerged as an important player in the oncogenic process. It is essential for the formation of, amongst other structures, the heart, limbs, mammary glands, teeth and genitalia and haploinsufficiency of the human TBX3 gene results in ulnar-mammary syndrome (UMS) which is characterised by malformations of these organs and body structures. On the other hand, the overexpression of TBX3 is a feature of a wide range of cancers and it has been implicated in several aspects of the oncogenic process ranging from the bypass of senescence to the inhibition of apoptosis, migration and invasion. However, little is known about the molecular basis for the role of TBX3 in development and oncogenesis because there is a paucity of information regarding its upstream regulators, its target genes as well as the protein co-factors that it co-operates with to execute its functions.
TBX3 gene and protein structure
Tbx3 forms part of the Tbx2 subfamily of T-box factors, which comprise the closely related Tbx2, Tbx3, Tbx4, and Tbx5, all of which originated from a single ancestral gene (8) . Based on the branch length of their phylogenetic tree, it is proposed that Tbx3 was duplicated by unequal crossing over events, giving rise to two gene clusters, namely Tbx2/Tbx3 and Tbx4/Tbx5. An additional duplication of this cluster gave rise to four separate genes, with Tbx2 and Tbx4 being situated on chromosome 17q23 and Tbx3 and Tbx5 on chromosome 12q24 in humans (8) (9) (10) . Due to the original duplication event, TBX3 is more closely related to TBX2 and in humans they share a 95% identity within their DNA binding domain and approximately 70% homology in their N-termini (11) .
In humans, TBX3 maps to the reverse strand of chromosome 12 at position 12q23-24.1 and alternative splicing results in a number of transcript variants with TBX3 and TBX3+2a being the most extensively studied (9) . Fan et al. showed that, while TBX3 and TBX3+2a are widely expressed in both mouse and human tissue, their expression ratio is species and tissue dependent (12) . The human TBX3 coding region spans approximately 4.7 kb, contains 7 exons and encodes a 723 amino acid protein ( Figure 1 ). Differential splicing of the second intron, however, results in the addition of the 2a exon, producing the TBX3+2a isoform with an additional 20 amino acids in the T-box domain (12, 13) . It is still unclear whether these variants have overlapping or distinct roles and whether the +2a insertion results in TBX3+2a regulating different target genes to TBX3. Indeed, Fan et al. reported that the isoforms were functionally distinct as, while the overexpression of TBX3 inhibited senescence in mouse embryonic fibroblasts (MEFs), the overexpression of TBX3+2a promoted this process (12) . These functional differences were ascribed to the fact that TBX3, and not TBX3+2a, was able to bind to the consensus T-element in vitro. These findings were contradicted by Hoogaars et al. who showed that both isoforms bound the consensus T-element in in vitro binding assays, repressed the T-elements previously identified in the Natriuretic peptide A (Nppa) and p21WAF1 promoters, and interacted with the homeobox co-factor NK2 homeobox 5 (Nkx2.5) (14) . In addition, using an in vivo transgenic mouse model they showed that TBX3 and TBX3+2a were capable of inhibiting heart chamber formation through repression of the cardiac chamber markers Nppa and Gap junction alpha-5 (Gja5). Furthermore, a more recent study suggested that, while the overexpression of Tbx3 and Tbx3+2a inhibited Nanog promoter activity in pluripotent mouse embryonic stem cells (mESCs), only Tbx3+2a physically interacted with Nanog (15) . Lastly, Kumar et al. highlighted a novel role for TBX3 in the regulation of RNA splicing and showed that both isoforms regulated this process (16) . In summary, while more work is needed to clarify these conflicting findings, it seems likely that the expression pattern and roles of TBX3 and TBX3+2a may vary depending on the cellular context.
The functional domains of the TBX3 protein ( Figure  1B ) were mapped using a Gal4 binding domain fused to different regions of Tbx3 on a luciferase reporter driven by four proximal promoter Gal4 binding sites (17) . Constructs expressing either the full length TBX3 protein or the 123-200 or 567-623 regions of the protein led to a repression of relative luciferase activity. This indicated that TBX3 was a transcriptional repressor and identified regions 567-623 and 123-200 as repression domains, which the authors called R1 and R2, respectively. Indeed, TBX3 was subsequently shown to transcriptionally repress p14ARF/p19ARF, p21WAF1, Nppa, E-cadherin, and phosphatase and tensin homolog (PTEN) (7) . Furthermore, when R1 or R2 were fused to the VP16 (herpes simplex virus protein 16) activation domain and tested in similar experiments, R1 but not R2, was able to override the VP16 activation domain and to repress transcriptional activity (17) . This led to the suggestion that R1 is the dominant repression domain. A putative activation domain at amino acids 423-500 was also mapped and indeed TBX3 has been shown to activate Connexin43 (18) and Gata6 (19) which are both important in heart embryogenesis. Using electrophoretic mobility shift assays (EMSA) the DNA-binding region was found to be located in the N-terminus (position 105-287 (REFSEQ: accession NM 005996.3)) and a with its extensive expression pattern, TBX3 contributes to the formation of many tissues with its most well characterised roles being in heart, mammary gland and limb development (24) . As mentioned earlier, haploinsufficiency of TBX3 causes the human autosomal dominant UMS which is characterised by a wide range of congenital abnormalities including malformations of the limbs, mammary gland aplasia, loss of areola and defects in the jaw, heart and genitalia (24) . These abnormalities can also be observed in mouse models of UMS. For example, homozygous mice die in utero around embryonic day E12.5 due to heart abnormalities and embryos exhibit mammary gland aplasia and posterior limb abnormalities (25) . Heterozygous mice exhibit minor aberrations of the external genitalia and have a significantly higher incidence of failed nipple and ductal tree development at E18.5 and adult virgins have aplasia of the first three pairs of mammary glands (25, 26) . It is important to note that there is a large number of tissues and organs where TBX3 is expressed but which are unaffected by UMS, suggesting that specific doses of TBX3 may be required for its functions in different tissues. This is in line with observations that the severity of the UMS phenotype correlates with the level of TBX3 deficiency (24) . It is also possible that other T-box factors, such as TBX2, could compensate for TBX3 in tissues and organs unaffected by UMS.
Consistent with the very early expression of Tbx3 in the inner cell mass of the blastocyst are numerous studies showing that TBX3/Tbx3 can promote both self-renewal and differentiation of embryonic stem cells (ESCs) which play important roles in maintaining homeostasis during embryonic development (27) . The maintenance of ESC pluripotency involves orchestrated signalling pathways and transcriptional networks including the leukaemia inhibitory factor/signal transducer and activator of transcription (LIF/STAT) pathway, as well as the pluripotency and self-renewal transcription factors, octamer-binding transcription factor 4 (Oct4), Nanog and Sox2. Ivanova et al. showed that while Tbx3 levels were high in undifferentiated mouse ESC (mESC), they were significantly down-regulated in mESCs undergoing retinoic acid (RA) induced differentiation (28) . They also demonstrated that high levels of Tbx3 could block differentiation into mesoderm, ectoderm, trophectoderm and neural crest cells. In support of these findings, Tbx3 was shown to be sufficient to maintain self-renewal of mESCs downstream of LIF/STAT signalling (29) . Interestingly, microRNA (miRNA)-137, which plays important roles in neural stem cell differentiation, was recently shown to directly repress Tbx3 levels by binding its 3' UTR in mESC (30) . This repression was also shown to result in disruption of mESC self-renewal and accelerated differentiation in vitro. More recently, Cioffi et al. also showed that miR-93 represses Tbx3 and thereby counteracts self-renewal in early adipocyte precursors (31) . nuclear localization signal (NLS) was found at residues 292 to 297 (17) . Bamshad et al. characterised mutations in 75 UMS sufferers, from 8 different families and reported that 50% of the mutations resided in the exons encoding the T-box domain and the other 50% occurred in downstream exons which encode the C-terminus (13) . Together, these reports highlight the importance of the T-box DNA binding domain and C-terminal regions of TBX3. Further characterisation of the structure of the TBX3 protein and its interaction with DNA were shown by Coll et al. when they solved the crystal structure of the TBX3 DNA-binding domain (20) . While they demonstrate that TBX3 binds the palindromic consensus T-box binding site as two independent monomers, it is predicted that TBX3 will bind its physiological targets as a single monomer.
As is the case with other T-box factors, it is speculated that post-translational modifications and interaction with co-factors may regulate TBX3 target gene specificity within different cellular contexts but these areas remain poorly understood (21) . Indeed, in addition to repressing its known target genes through direct binding to a T-element it can also recruit histone deacetylase (HDAC) 1, 2, 3 and 5 to epigenetically silence promoters and the details will be discussed under relevant sections of this review. Interestingly, mass spectrometry analysis performed in the Moon laboratory revealed that TBX3 interacts with a number of RNA-binding and -splicing proteins which indicated novel roles for TBX3 (16, 22) . Furthermore, they showed that mutations in the TBX3 NLS, representative of those seen in UMS, disrupt its interaction with its RNA-binding partners. They also reported that TBX3 binds its target RNAs through T-elements present within mRNA transcripts and could directly regulate the alternative splicing of Disks large homolog (3Dlg3) and Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (Nfκb1). TBX3 was also shown to facilitate the recruitment and docking of other RNA-binding proteins and splicing factors, such as the RNA helicase, DEAD box helicase 3 (DDX3), to T-element containing RNAs. Interestingly, the UMS mutations present within the C-terminal region of TBX3 interfered with its RNA splicing functions.
The above findings demonstrate that TBX3 can regulate gene expression at multiple levels.
TBX3 in development and in stem cell biology
During mouse development Tbx3 is first expressed in the morula, then in the inner cell mass of the blastocyst and at the onset of gastrulation it localises to the proximal pole of the epiblast (23) . It is subsequently found in distinct areas of the developing nervous system, musculoskeleton, eye, heart, kidney, lung, liver, pancreas and mammary gland (24) . TBX3 is also widely expressed in a number of human foetal organs and tissues, including heart, lung, kidney, liver and spleen (13). Consistent Lu et al. also showed that Tbx3 overexpression in mESCs promotes differentiation into the extra-embryonic endoderm (ExEn) lineage through direct regulation of the ExEn regulator, Gata6 (19) . Furthermore, they showed that Tbx3 knockdown during embryoid body formation prevented extra-embryonic endoderm differentiation but enhanced ectoderm and trophectoderm differentiation. In addition, Zhao et al. showed that the overexpression of either Tbx3 or Tbx3+2a in ESCs or induced pluripotent stem cells (iPSCs) could induce differentiation by inhibiting the transcriptional activity of Nanog (15) . This was further demonstrated by studies showing that Tbx3 is highly expressed in definitive endoderm progenitor cells and as mentioned earlier, complexes with the histone demethylase, JmjC domain-containing protein 3 (Jmjd3), to transcriptionally activate Eomes and promote endoderm differentiation (32, 33) . Another mechanism by which Tbx3 promotes endoderm differentiation is through the canonical Wingless (Wnt) signalling pathway, where Tbx3 is a downstream effector of Wnt3a and promotes the induction of a primitive endoderm state, giving rise to visceral endoderm (34) . Interestingly, Waghray et al. recently showed using expression studies and chromatin immunoprecipitation (ChIP) sequencing that Tbx3 directly represses Developmental pluripotencyassociated protein 3 (Dppa3) at a region 1.7 kb upstream of its transcriptional start site and consequently induces differentiation of ESCs towards the mesoderm (35) . In addition to this, they identified a Wnt/Tbx3/Dppa3 signalling axis that regulates the balance between mESC self-renewal and differentiation, which may provide one possible explanation for how Tbx3 may either promote or inhibit differentiation.
Tbx3 has also been implicated in the generation of mouse iPSCs by, in part, directly activating the Oct4 promoter (36) . In addition, Tbx3 was shown to improve the generation of porcine iPSCs when co-expressed with Oct4, Sox2, Kruppel-like factor 4 (Klf4) and c-Myc (36) . Furthermore, iPSC formation increased when Tbx3 expression was enhanced by Zinc finger protein of the cerebellum 3 (Zic3) (37) . Ectopic overexpression of Tbx3 in the atria of the adult mouse heart was also shown to reprogramme mature differentiated atrial myocytes into a more naïve pacemaker phenotype by repressing genes required for the working myocardial function and stimulating genes required for pacemaker functions (38) . ESCs and iPSC cells can sporadically enter a "two-celllike embryonic state" (2C-state) which is important for ESC potency (39) . Dan et al. showed that in 2C mESCs, Tbx3 could activate the promoter activity of a 2-cell gene, zinc finger and SCAN domain-containing protein 4 (Zscan4) and that ectopic overexpression of Tbx3 in these cells resulted in telomere lengthening and genomic stability (40) .
The role of TBX3 in promoting differentiation of human ESC (hESC) is somewhat different to that of mESCs, as it promotes neuroepithelial differentiation but not endoderm differentiation (41) . This is possibly due to the different pluripotent states of hESC and mESCs, with mESCs being in a more naïve state (42) . TBX3 overexpression cell culture models showed that it could promote hESC proliferation by repressing p14ARF and NFκBIB, an inhibitor of the NF-kappaB (NF-κB) pathway (41) . The knockdown of TBX3 on the other hand resulted in decreased expression of neuroepithelial and neuroectoderm markers paired box 6 (PAX6), LIM homeobox 2 (LHX2), forkhead box G1 (FOXG1), and retina and anterior neural fold homeobox (RAX). Taken together, these studies reveal important, contextdependent roles for TBX3 in the maintenance, selfrenewal and differentiation of ESC populations.
TBX3 and cancer
TBX3 is overexpressed in a range of carcinomas (breast, pancreatic, melanoma, liver, gastric, lung, head and neck, ovarian and bladder) and sarcomas (chondrosarcoma, fibrosarcoma, liposarcoma, rhabdomyosarcoma and synovial sarcoma) (7, 43, 44) . Importantly, there is substantial evidence that this overexpression contributes to the oncogenic process at multiple levels including the bypass of senescence and apoptosis as well as the promotion of proliferation, tumour formation and invasion ( Figure 2 ). In addition, recent studies suggest that there are cancer contexts where TBX3 may also function as a tumour suppressor (Figure 2 ). Given the myriad of cancer processes that TBX3 impacts it is expected to co-operate with other oncogenic factors and to regulate several target genes. There is, however, limited information regarding these areas and nothing is known about what enables TBX3 to switch between tumour promoter and tumour suppressor.
TBX3 in senescence, apoptosis and proliferation
In response to endogenous or exogenous stress signals such as oncogenic stimuli, cells can undergo cell cycle arrests, senescence or apoptosis which protect against inappropriate cell division and/or survival. These processes serve as important barriers to cancer and are regulated at a molecular level by the p14ARF/p53/p21 and p16INK4a/retinoblastoma protein (pRB) tumour suppressor pathways. The inhibition or bypass of these pathways are required for cancer initiation and progression as well as the development of anti-cancer drug resistance.
Senescence is an irreversible/permanent exit from the cell cycle and Tbx3 can bypass this process and consequently immortalise mouse embryonic fibroblasts (MEFs) and ST.HdhQ111 striatal cells through either directly binding or repressing a T-element in the initiator of p19ARF/p14ARF or by recruiting HDAC 1, 2, 3 and 5 to epigenetically silence its promoter (7, 45) . A recent study by Kumar et al. demonstrated that TBX3 can also bypass senescence by indirectly repressing p16INK4a (22) . Indeed, the authors show that Tbx3 in complex with Coactivator of AP1 and Estrogen Receptor (CAPERα) represses the long non-coding RNA, Urothelial Cancer Associated 1 (UCA1) and this prevents the stabilization of p16INK4a mRNA (22) . Furthermore, they showed that RAS-induced senescence of human foreskin fibroblasts resulted in dissociation of the CAPERα/TBX3 complex and a concomitant increase in UCA1 and p16INK4a expression. It would be worth investigating whether the CAPERα:TBX3 interaction and UCA1 repression is required for senescence bypass in TBX3 driven cancers.
Apoptosis, a form of programmed cell death, plays an essential role in the maintenance of tissue homeostasis and negative regulation of this cellular process promotes malignant transformation and chemoresistance (46) . There is evidence that TBX3 may contribute to oncogenesis and confer anti-cancer drug resistance by compromising the apoptotic pathway. Indeed, TBX3 co-operated with the Myc oncogene to transform MEFs, where it promoted the bypass of Myc induced apoptosis through the downregulation of p19ARF and p53 levels (47) . In addition, TBX3 has been shown to inhibit apoptosis in rat bladder hyperplastic epithelial cells and TBX3 knockdown increased apoptosis in rat bladder carcinoma cells (7) . TBX3 was also linked to protecting cells against anoikis which is a form of apoptosis that occurs when anchorage dependent cells become detached from the surrounding extracellular matrix and its bypass is associated with epithelial mesenchymal transition (EMT). Indeed, head and neck squamous cell carcinoma (HNSCC) cells depleted of TBX3 underwent anoikis (7). The overexpression of TBX3 or TBX3+2a in kidney mesangial cells was also reported to result in the evasion of serum starvationtriggered apoptosis (48) . Furthermore, silencing Tbx3 in rat bladder carcinoma cells rendered the cells sensitive to doxorubicin-induced apoptosis and the overexpression of TBX3 was associated with a chemotherapy-resistant phenotype (49) . Similar findings showed that knocking down TBX3 sensitized human colorectal carcinoma cells to doxorubicin via activating the p14ARF-p53 pathway (50) .
A number of studies also support a role for TBX3 in promoting cell cycle progression and proliferation through its ability to disrupt the p19ARF-p53-p21 pathway. Indeed, TBX3 protein and mRNA levels peak in S-phase and chondrosarcoma cells in which TBX3 is depleted accumulate in S-phase with a corresponding increase in p19ARF, p53 and p21 levels (51). The TBX3 is overexpressed in numerous cancers where it promotes several aspects of the oncogenic process including the bypass of senescence, uncontrolled proliferation, migration, metastasis and drug resistance. In some cancers, the key oncogenic signalling pathways responsible for this overexpression have been identified (see cancer types in brackets and colour coding which match the appropriate oncogenic processes). Right panel: TBX3 also exhibits tumour suppressor activity. It is silenced by methylation in certain cancers and it retards proliferation, cell migration and tumour formation of fibrosarcomas. The factors upstream of TBX3 as well as the co-factors and target genes that mediate the tumour suppressor functions of TBX3 are yet to be elucidated.
increased levels of TBX3 in S-phase were shown to occur transcriptionally through activation by c-Myc at E-box motifs located at -1210 and -701 bps and posttranslationally by cyclin A-CDK2 phosphorylation (51) . Together these results suggest that TBX3 functions as a pro-proliferative factor, in part, by promoting transition into G2/M. TBX3 can also promote cell proliferation of mammary epithelial cells (MECs) by repressing 19ARF, which was accompanied by the down-regulation of p21 (52) 
-/-mouse livers exhibit increased p19ARF and p21 levels although p53 levels remained unaffected (53) . Importantly, TBX3 can promote cell proliferation by directly binding and repressing the p21 promoter via a consensus T-element which requires the T-box and R2 repression domains (14, 54) . It is interesting to note that TBX2 directly represses the p21 promoter through the same T-element (7). It would therefore be interesting to determine whether TBX2 and TBX3 have redundant pro-proliferative roles in repressing the p21 promoter in cancers where they are both expressed or whether additional factors, such as post-translational modifications and/or the availability of co-factors, will determine which of the two T-box factors regulates p21.
TBX3 may also impinge on other cellular pathways to promote cell cycle progression and proliferation. For example, an inverse correlation between the mRNA and protein levels of TBX3 and the tumour suppressor PTEN was identified in HNSCC cells (55) . PTEN is a negative regulator of the phosphoinositide 3-kinase/ Protein kinase B (PI3K/AKT) pathway and suppresses oncogenic processes such as proliferation, cell survival and migration (56) . Importantly, TBX3 can directly repress PTEN by binding a 132 bp DNA region within its promoter (55) . Interestingly, the authors found that this region of the PTEN promoter does not contain a T-element and thus speculated that TBX3 may repress PTEN by either interacting with transcriptional corepressors or by interfering with positive activators of PTEN. It would be interesting to determine the functional significance of PTEN repression by TBX3 especially on cell proliferation, survival and migration.
TBX3 has also been shown to negatively regulate proliferation in support of cell migration, a phenomenon known as the proliferation/migration dichotomy (57, 58) . Knocking down TBX3 by shRNA inhibited migration and enhanced proliferation of breast cancer and melanoma cells which was accompanied by a decrease in the expression of p14ARF, p53 and p21 (57) . Furthermore, ectopic overexpression of TBX3 in non-invasive WM1650 radial growth phase (RGP) melanoma cells and the upregulation of TBX3 by RA in vertical growth phase (VGP) melanoma cells reduced the proliferative capacity of the cells with the former being associated with an increase in migratory ability (58, 59) . It is important to note that Transforming growth factorbeta (TGF-β) contributes to breast cancer progression by inhibiting cell proliferation and promoting migration and recent studies have shown that TBX3 is required for the anti-proliferative and pro-migratory effects of TGF-β in breast epithelial cells (60, 61) . The mechanism(s) that determines whether TBX3 functions as a proproliferative or anti-proliferative factor is not known.
TBX3 in tumour formation, invasion and metastasis
TBX3 has also been shown to contribute to tumour formation, migration and invasion (Figure 2, left panel) . Indeed, knockdown of TBX3 reduced anchorageindependence of colon and hepatoma carcinoma cell lines and when these cells were engineered to express a Tbx3 mutant, they had significantly reduced ability to form tumours in nude mice (49 (64) . Several lines of evidence suggest that TBX3 also plays an important role in the transition of non-malignant RGP melanoma to a malignant VGP melanoma. TBX3 levels increase specifically in VGP and metastatic melanoma cells and whereas ectopic overexpression of TBX3 in RGP melanoma cells was sufficient to promote tumour forming ability and invasion, knockdown of TBX3 in VGP cells inhibited migration and tumour formation (57, 58) . The overexpression of TBX3 has also been positively linked to migration and invasion of pancreatic ductal adenocarcinoma (PDAC). Compared to normal adjacent and healthy donors, PDAC tissue samples had increased levels of TBX3 mRNA and stained positive for TBX3 protein (65) . Furthermore, in vitro assays show that overexpression of TBX3 in Pan1 and BxPC3 pancreatic cell lines significantly enhanced their migratory ability and invasion potential and xenotransplantation experiments revealed that TBX3 overexpressing Pan1 and BxPC3 cells induced significantly larger tumours than their controls. It is interesting to note that the TBX3 overexpressing tumours expressed the angiogenesis associated markers FGF2 and VEGFA which suggests that TBX3 may also be involved in angiogenesis in PDAC. More recently, TBX3 was also linked to tumour formation and migration in several sarcoma subtypes. Ectopic overexpression of TBX3 in chondrosarcoma cells enhanced their ability to form tumours in mice and knockdown of TBX3 inhibited migration of chondrosarcoma, liposarcoma and rhabdomyosarcoma cells (44) .
Decreased expression of E-cadherin in several cancers including melanoma, breast, ovarian and nonsmall cell lung carcinoma have been shown to be associated with tumour invasiveness, metastasis and poor patient prognosis (66) . There is good evidence to suggest that a key mechanism by which TBX3 promotes these oncogenic processes is through its ability to repress E-cadherin. A study by Rodriguez et al. showed that increased expression of TBX3 correlated with low levels of E-cadherin in metastatic melanoma tissue samples (67) . The authors further established using melanoma cells that TBX3 directly binds and represses the E-cadherin promoter in vitro and in vivo through a half consensus T-element close to the transcription initiation site. This repression was shown to be physiologically relevant because when TBX3 was silenced in metastatic melanoma cells, E-cadherin levels increased. Furthermore, TBX3 is transcriptionally indirectly upregulated by the oncoprotein BRAF V600E, which is constitutively activated in 50% of melanomas, and is a substrate and effector of AKT3, which is activated in ~70% of advanced stage melanomas where it plays a critical pro-invasive role (68, 69) . Importantly, TBX3 was shown to repress E-cadherin downstream of both these pathways to promote migration and invasion of melanoma cells. Interestingly, phosphorylation of TBX3 by AKT3 in melanoma enhanced its ability to repress E-cadherin and phosphorylation of TBX3 by p38 in normal kidney cells decreased E-cadherin protein levels (70) . This suggests that phosphorylation may play an important role in modulating TBX3 target gene regulation. Elevated levels of TBX3 were also shown to correlate with decreased E-cadherin levels in squamous carcinoma cells (71) . In addition, work by Du et al. revealed that a PKC/TBX3/E-cadherin signalling cascade exists in human bladder cancer cells and that the regulation of E-cadherin by TBX3 occurs in a PKC-dependent manner (72) . It is noteworthy that in sarcomas, the ability of TBX3 to promote migration was not due to E-cadherin repression. This suggests that the molecular mechanism(s) underlying the pro-migratory role of TBX3 in different cancers may be different and future studies identifying TBX3 target genes as well as signalling pathways that upregulate TBX3 would likely shed light on this.
TBX3 and cancer stem cells
Cancer stem cells (CSCs) are a biologically distinct subpopulation of tumour cells which have indefinite potential for self-renewal and they are thought to ultimately drive tumourigenesis. In addition, CSCs are often not targeted by traditional chemotherapeutic agents and are associated with drug-resistance and clinical relapse after remission (73) . A study by Fillmore et al. revealed that the addition of oestrogen to a number of ERα-positive breast cancer cell lines resulted in a dramatic increase in the number of CSCs which required TBX3 (63) . Importantly, the knockdown of TBX3 significantly reduced CSC numbers in a variety of breast cancer cell lines and abrogated their ability to form tumourspheres, a spherical formation reported to be generated by the proliferation of a single CSC. On the other hand, TBX3 overexpression resulted in a significant increase in CSC numbers, tumoursphere-forming ability and a more than 100-fold increase in tumour-seeding potential in vivo. A recent study by Perkhofer et al. also demonstrated that TBX3 overexpressing pancreatic cancer cells had increased sphere-forming ability and that TBX3 induced the CSC phenotype of primary pancreatic cancer cells by regulating NODAL/ACTIVIN signalling through an autocrine positive feedback loop (65) . In light of this, it would be interesting to determine whether TBX3 impacts similarly on CSCs in other cancers and if this is an additional mechanism through which it contributes to cancer development and anti-cancer drug resistance.
The tumour suppressor role of TBX3
In contrast to the large body of work implicating TBX3 as an oncoprotein, there are also studies that have implicated it as a tumour suppressor ( Figure  2, right panel) . Using microarray analyses, Lyng et al. demonstrated that TBX3 gene expression is downregulated in uterine cervical cancer samples, which strongly correlated with lymph node metastasis and reduced progression-free patient survival (74) . Subsequent studies have also shown that TBX3 levels are epigenetically silenced by methylation in glioblastoma, gastric, bladder and prostate cancer (7). Yamashita et al. examined methylation-silenced genes in gastric cancer and revealed that the TBX3 promoter is methylated in at least one primary gastric cancer, but not normal gastric mucosa (75) . TBX3 methylation was subsequently revealed to be associated with a significantly lowered survival rate in a cohort of glioblastoma patients (76) . Following this, White-al Habeeb et al. demonstrated that TBX3 is differentially methylated in Gleason score (GS) 8 vs GS6 prostate cancer tumour samples, with increased methylation occurring in the more aggressive GS8 samples (77) . Collectively these studies suggest that under certain circumstances TBX3 suppression may promote cancer progression. Furthermore, a study investigating the genome-wide methylation pattern of fresh-frozen bladder cancer tumour tissue revealed that TBX3 methylation is associated with the progression of non-muscle invasive human bladder tumours (Pta) to muscle-invasive tumours (MI) (78) . The authors of this study also showed that TBX3 methylation was an independent predictor of bladder cancer progression and that it correlated with reduced progression-free survival. In a follow-up study, the same group performed methylation analyses on formalin-fixed paraffinembedded tumour tissue from 192 patients with Pta, 40% of whom experienced progression to MI (79) . They demonstrated that patients with low TBX3 methylation experienced significantly increased progressionfree survival and that, within 10 years of follow-up time, TBX3 was an independent prognostic marker of progression risk. Interestingly, both studies revealed that methylation of the TBX3 homologue, TBX2, was also linked to tumour progression of bladder cancer (78, 79) .
The above studies together suggested that TBX3 may function as a tumour suppressor and a comprehensive characterisation of the tumour suppressor role of TBX3 was recently provided by Willmer et al. (44) . The authors showed that the TBX3 protein is upregulated in a number of transformed fibroblast and fibrosarcoma cell lines and tissues. Using TBX3 overexpressing and knock down fibrosarcoma cell culture models they demonstrated that TBX3 discourages substrate-dependent and -independent cell proliferation, migration and tumour formation. Importantly, whereas the knockdown of TBX3 was able to significantly increase the in vivo tumour forming ability of fibrosarcoma cells in a mouse model, TBX3 overexpressing cells formed smaller tumours in the same model. These results demonstrate that TBX3 behaves as a tumour suppressor in transformed fibroblast and fibrosarcoma cells, suggesting it may function as either oncoprotein or tumour suppressor depending on cellular context. It will be important to elucidate the molecular mechanism(s) that enables it to switch between these functions.
Signalling pathways that regulate TBX3 expression in cancer
Despite the catastrophic effects observed when TBX3 expression is deregulated very little is still known about the signalling pathways that regulate TBX3 levels. In the last few years some developmental pathways, that are important in cancer, have been implicated and these will be discussed below and are indicated in Figure 2. 
Wnt/β-catenin signalling pathway
The canonical Wnt/β-catenin pathway plays critical roles during embryogenesis and adult tissue homeostasis, where it regulates a number of key processes including proliferation, differentiation and cell fate determination (80) . Aberrant activation of the Wnt/β-catenin pathway, often caused by constitutive activation of β-catenin, has been implicated in a number of cancers and Renard et al. have suggested that TBX3 is a direct target of this pathway in liver tumourigenesis (49) . Using microarray analyses, they demonstrated that TBX3 is upregulated in mouse hepatocellular carcinoma (HCC) tumour samples carrying an active mutant form of β-catenin. In addition, the authors revealed a correlation of increased TBX3 expression with a mutant active form of β-catenin in human and mouse HCC and human hepatoblastoma. Furthermore, they demonstrated that β-catenin, in complex with its co-activator Tcf, directly activated the TBX3 promoter through a Tcf-binding element, resulting in enhanced proliferation, tumour formation, as well as protection from doxorubicin-induced apoptosis. The authors concluded that TBX3 is a key mediator of the proliferation and survival activities of β-catenin in liver tumourigenesis.
Following this, Lachenmayer et al. investigated the effect of the multi-kinase inhibitor Sorafenib, the only Food and Drug Administration (FDA) approved drug for HCC treatment, on the human HepG2 HCC cell line (81) . They showed that Sorafenib inhibits β-catenin levels with a corresponding reduction in TBX3 mRNA levels. In addition, one of the oldest and best known Chinese herbal medicines, rhubarb root, is used to treat liver disease and exhibits anti-cancer properties through the induction of apoptosis in a number of cancers (82) . Tsai et al. found that it also attenuates Wnt/β-catenin signalling in human HCC cells which was accompanied by decreased TBX3 protein levels (82) .
Interestingly, a study by Cavard et al. suggests that the regulation of TBX3 by the Wnt/β-catenin pathway may not be limited to liver cancer (83) . They examined gene expression profiles in solid pseudopapillary pancreatic neoplasms where the Wnt/β-catenin pathway is aberrantly activated and demonstrated that TBX3 mRNA is overexpressed. The interplay between Wnt signalling and TBX3 was also reported by Arendt et al., who showed that both Wnt and TBX3 could regulate proliferation of human breast progenitor cells and that TBX3 induced autocrine Wnt signalling in these cells, possibly via a feedback loop (84).
Fibroblast growth factor (FGF) signalling pathway
FGF signalling has been shown to be important for the regulation of cell proliferation, survival, migration as well as differentiation, and deregulated FGF signalling is important for the pathogenesis of a number of cancers (85) . It is well established that TBX3 regulates this signalling pathway during mammary gland development and it has also been suggested that TBX3 lies downstream of FGF (86) . Fillmore et al. demonstrated that oestrogen and FGF signalling upregulated the expression of TBX3 in breast cancer (63) . Treatment of ERα-positive breast cancer cell lines with oestrogen resulted in a substantial increase in secreted FGF9, which in turn resulted in significantly increased TBX3 mRNA and protein levels. Importantly, when cells were treated with oestrogen and an FGF9 inhibitor this was decreased, while treatment with both oestrogen and FGF9 resulted in an even greater increase in TBX3 mRNA and protein expression. Similarly, when ERα-negative breast cancer cell lines were treated with FGF9, there was a marked increase in TBX3 protein, suggesting that this regulation is not specific to ERα-positive breast cancer. Taken together, these findings suggest that FGF signalling mediates the upregulation of TBX3 by oestrogen in breast cancer and, as mentioned previously, promotes the expansion of breast CSCs.
Protein kinase C (PKC) signalling pathway
The PKC family consists of phospholipid-dependent serine/threonine-specific protein kinases which mediate various cellular functions including proliferation, apoptosis and differentiation (87) . The deregulation of PKC signalling has been implicated in cancer, including breast cancer where it promotes tumourigenesis by modulating cell proliferation, migration, apoptosis and survival (87) . Many studies which have investigated the role of the PKC pathway have employed the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA, also called PMA) which activates PKC isoforms by translocating them to specific cellular compartments (87) . Mowla et al. showed that in prostate epithelial and lung fibroblast cells, PMA, increased TBX3 mRNA and protein in a PKC-dependent manner (64) . Furthermore, they demonstrated that the activator protein-1 (AP-1) transcription factors, c-Jun and JunB, bound a degenerate PMA response element in the TBX3 promoter, mediating its upregulation. Finally, as mentioned previously, they showed that TBX3 mediated the pro-migratory effect of PMA in MCF7 breast cancer cells. The regulation of TBX3 by the PKC pathway has been further supported by Du et al. who showed that knocking down Phospholipase C epsilon (PLCε) in bladder cancer cell lines resulted in a corresponding inhibition of PKCα/β, which in turn reduced TBX3 mRNA and protein levels (72) . Importantly, they also demonstrated that in bladder cancer the repression of E-cadherin by PKCα/β signalling is mediated by TBX3.
Retinoic acid (RA) signalling pathway
All-trans RA, a metabolite of vitamin A (all-trans-retinol), plays an important role in embryo development, where it regulates gene transcription to modulate a number of biological processes, including cell proliferation, differentiation and apoptosis (88) . Compromised RA signalling often occurs early in tumourigenesis, including in breast cancer (89) . Initial studies provided a preliminary indication that TBX3 may be regulated by the RA pathway in the development of chick and mouse limbs (90, 91) . Ballim et al. confirmed this regulation during mouse limb development and expanded these findings to show that RA treatment of the ME1402 VGP melanoma cell line resulted in a substantial increase in TBX3 mRNA and protein, and a correlative decrease in proliferation (59) . Furthermore, knockdown of TBX3 expression by a shRNA approach significantly reduced the growth-inhibitory effect of RA. Finally, the authors demonstrated that RA transcriptionally activates TBX3 through directly binding a degenerate RA response element half site at -87 bp. Together these results suggest that TBX3 partly mediates the RA-regulated inhibition of cell proliferation in the human melanoma cell line tested.
Transforming growth factor-beta 1 (TGF-β1) signalling pathway
The TGF-β growth factor cytokine family is composed of a large number of secreted polypeptides that activate cellular responses involved in development, homeostasis and the immune system (92) . In addition, TGF-β1 signalling has been widely reported to have a dual role in the progression of cancer. While it acts as a tumour suppressor and inhibits cell proliferation during the early stages of carcinogenesis, it promotes migration and metastasis in the late stages of the disease (92) . Similar to TBX3, TGF-β1 signalling is critical for the development of the mammary glands but also contributes to breast cancer progression through the inhibition of cell proliferation and promotion of migration (93) . Importantly, Li et al. demonstrated that TGF-β1 treatment transcriptionally upregulated TBX3 in breast epithelial and keratinocyte cells (61) . They showed that JunB and Smad4 mediate this effect and directly bind to the TBX3 promoter at a degenerate Smad Binding Element (SBE). The authors also revealed that TBX3 mediated the anti-proliferative and pro-migratory effects of TGF-β1 in these cells. In a follow-up paper they demonstrated that this anti-proliferative function involves the ability of TBX3 to directly bind and repress the pro-proliferative factor TBX2 (60) . Finally, they showed that the TGF-β1/TBX3/TBX2 axis resulted in the upregulation of p21WAF1, leading to cell cycle inhibition. Recent work by Wensing & Campos also showed that TGF-β1 treatment of immortalised human mesangial cells resulted in a substantial increase in TBX3 and TBX3+2a mRNA which resulted in the evasion of serum starvation-triggered apoptosis (48) . These findings suggest that TGF-β1 may upregulate TBX3 to simultaneously inhibit proliferation but bypass apoptosis. However, more work is needed to explore this further.
Phosphatidylinositol 3-kinase/Protein kinase B (PI3K/Akt) signalling pathway
PI3Ks constitute a lipid kinase family that activate the serine/threonine kinases, Akt1, Akt2 and Akt3. These highly homologous isoforms phosphorylate a plethora of substrates that are involved in the regulation of key cellular processes including cell proliferation, apoptosis, and migration (94) . It is well established that constitutive activation of Akt, through PI3K amplification or PTEN mutation, contributes to the oncogenic process and is associated with a poor prognosis and resistance to chemo-and radio-therapy (94) . Indeed, Akt activation is one of the most frequent molecular alterations in cancers, including melanoma, gastric, pancreatic, breast, sarcoma and prostate cancer (95) (96) (97) (98) . While there are instances where the three Akt isoforms are able to compensate for each other, recent research show that their tissue expression patterns and functions are different (99, 100) . The PI3K/Akt pathway is activated in 70% of all melanoma cases and Peres et al. reported that TBX3 is a substrate and effector of this pathway in melanoma (69) . Consistent with other reports, the authors demonstrated that Akt3 is the predominant isoform activated in a panel of human melanoma cell lines. Furthermore, Akt3 posttranslationally upregulated TBX3 expression through phosphorylation at S720 in ME1402 and MM200 VGP melanoma cells, which promoted protein stabilisation. Lastly, they demonstrated that TBX3 mediated the oncogenic activity of the PI3K/Akt pathway in these cells, as phosphorylation of TBX3 at this site resulted in increased nuclear localisation of TBX3 protein, repression of E-cadherin and promotion of migration and invasion.
Conclusion
The transcription factor TBX3 provides an important link between embryonic development and cancer. While mutations resulting in decreased levels of TBX3 lead to ulnar-mammary syndrome, increased levels of TBX3 are linked to several epithelial derived cancers and a diverse subset of soft tissue and bone sarcomas. Indeed, TBX3 is a key driver of a number of cancer processes including proliferation, tumour formation, invasion and metastasis and it has therefore been proposed as an important novel molecular target for anti-cancer treatments. There is also evidence that in certain cellular contexts TBX3 may function as a brake to prevent tumour progression. However, there is still very little known about the molecular mechanisms regulating the tumour promoting and tumour suppressor functions of TBX3 and what enables it to switch between these two roles. This information has important implications for targeting TBX3 in anti-cancer drugs especially since directly targeting TBX3 is unlikely to be a viable option. This could involve the following three approaches either alone or in combination: targeting signalling pathways required for TBX3 overexpression; targeting the enzymatic activities of TBX3 co-factors; and targeting the enzymatic activity of genes that encode enzymes that are activated by TBX3.
